How can Omeros Corp. (NASDAQ:OMER) punish you?


Omeros Corp. (NASDAQ:OMER), whose market capitalization now stands at $873.07M, reported EPS of $-1.46 in the last financial year. That indicates the stock has price-to-earnings ratio of – at the prevailing stock price. This fiscal year’s EPS is projected to grow 17.50% over the preceding year.

For the forward P/E metric, market analysts have a 12-month target price of $36.67 on the stock of Omeros Corporation.

Over the preceding five years, Omeros Corporation has recorded EPS improvement of -5.10%. That against sales growth of 55.90% over the same 5-year period.

Let’s look into the charts of the stock

The Barchart Technical Opinion rating is a 88% Buy with a Strongest short term outlook on maintaining the current direction. Longer term, the trend strength is in the Top 1%. Long term indicators fully support a continuation of the trend.

Omeros Corporation also recorded return assets of -100.30%, return on of 155.80% and return on investments of -141.50%.

Analysts are projecting the stock of Omeros Corporation to be trading at $36.67 in the next 12-months, but what been its performance quality until now?

The stock jumped/declined 26.49% in the previous week, and for the preceding month it is up/down 31.59%. For the quarter and for the fiscal year so far, the shares have risen/decline 78.32% and 97.38%, respectively. From a year earlier, the stock has moved 75.13%.

What about the volatility of the equity? First, the stock’s beta is 3.56. Investors would do well to note that beta of less than 1 indicates that the underlying security is less volatile as against the market, but beta over one implies that a security is extremely volatile compared to market.

In terms of monthly or weekly volatility, Omeros Corporation has a weekly volatility of 7.73% and monthly volatility of 4.97%.

Omeros Corporation (NASDAQ:OMER) today announced that the US Food and Drug Administration (FDA) has granted breakthrough therapy designation to OMS721 for the treatment of Immunoglobulin A (IgA) nephropathy. OMS721 is Omeros’ lead human monoclonal antibody targeting mannan-binding lectin-associated serine protease-2 (MASP-2), the effector enzyme of the lectin pathway of the complement system.